Send to

Choose Destination
Brain Stimul. 2017 Sep - Oct;10(5):926-933. doi: 10.1016/j.brs.2017.06.003. Epub 2017 Jun 9.

rTMS with a two-coil array: Safety and efficacy for treatment resistant major depressive disorder.

Author information

Butler Hospital, Brown Department of Psychiatry and Human Behavior, 345 Blackstone Blvd, Providence, RI 02906, United States. Electronic address:
Sheppard Pratt Health System Clinical Research Programs, 6501 N. Charles Street, Baltimore, MD 21204, United States. Electronic address:
Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR 97227, United States. Electronic address:
Departments of Psychiatry and Surgery, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, 1 Medical Center Drive, Lebanon, NH 03756, United States. Electronic address:
PRA Health Sciences (formerly CRI-Lifetree), 3838 South 700 East, Suite 202, Salt Lake City, UT 84106, United States. Electronic address:
Emory University Department of Psychiatry and Behavioral Sciences, Brain Health Center, 12 Executive Park Drive, NE, Floor 5, Atlanta, GA 30329, United States. Electronic address:
Rio Grande Neurosciences, Inc. (Formerly Cervel Neurotech, Inc.), 600 Central SE, Ste 221, Albequerque, NM 87102, United States. Electronic address:
Rio Grande Neurosciences, Inc. (Formerly Cervel Neurotech, Inc.), 600 Central SE, Ste 221, Albequerque, NM 87102, United States; Stanford University, Department of Psychiatry and Behavioral Sciences, 401 Quarry Road, Stanford, CA 94305-5717, United States; Stanford University Department of Neurosurgery, 213 Quarry Road, Palo Alto, CA 94304-5979, United States. Electronic address:



Therapeutic repetitive Transcranial Magnetic Stimulation (rTMS) has emerged as a standard of care for individuals with major depressive disorder (MDD) who do not benefit from, or are unable to tolerate, antidepressant pharmacotherapy. Depth of stimulation is limited with currently approved figure-eight coils and larger coils capable of deeper penetration may be associated with loss of stimulation focality and undesired recruitment of motor cortex. A second generation 2-coil array rTMS system was designed to target converging brain pathways for potentially deeper prefrontal cortex stimulation.


A randomized, double-blind, sham-controlled trial examined the safety and efficacy of an investigational 2-coil rTMS device. Antidepressant treatment-resistant or treatment-intolerant MDD patients (n = 92) received 20 daily rTMS treatments with coil centers positioned over left dorsolateral prefrontal cortex (dlPFC) and dorsomedial prefrontal cortex (dmPFC). 10 Hz stimulation (maximum summated power for both coils ≤ 120% motor threshold) was delivered. Primary efficacy endpoint was change in HAMD-24 score from baseline to the conclusion of treatments.


Data from n = 75 (per-protocol sample) showed significantly greater improvement (mean HAMD-24 change) over time for the active (n = 38) versus sham (n = 37) group after 20 sessions (F = 7.174; p = 0.008) and also at the one-month follow-up (F = 6.748; p = 0.010). Response rates were 55.3% (active) versus 32.4% (sham) (p = 0.063); remission rates were 26.3% versus 18.9% (p > 0.05). Other secondary outcomes were generally supportive.


The results confirmed safety and acute efficacy of the 2-coil rTMS device. Despite modest sample size, primary outcome was clinically and statistically significant, and the effect size was comparable with those reported for regulatory trials with FDA-cleared devices.


Depression; Multiple coil array; Randomized clinical trial; Transcranial magnetic stimulation

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center